Changes in the CLSI interpretive criteria for Enterobacteriaceae and Ertapenem

Clinical Microbiology Newsletter

Volumn 33, Issue 23, 2011, Pages 185-186

  Badal, Robert E ^a   Lewis, James S ^a   Motyl, Mary R ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; DRUG MONITORING; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 81455143528     PISSN: 01964399     EISSN: 18734391     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2011.11.002     Document Type: Letter

References (3)

1. Clinical Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement (June 2010 update). CLSI document M100-S20-U. Clinical and Laboratory Standards Institute, Villanova, PA.
2. Lewis, J. and J. Jorgensen. 2010. Abstr. 904. 48th annual meeting IDSA.
3. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, January 2011 http://www.eucast.org/clinical_breakpoints.